XNAS
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Former biotech Entero pivoted to AI energy optimization via acquisition, securing revolving credit facility. Minimal Q1 revenue of $38K signals early-stage transformation struggles.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | Q1 2026 | — | -0.82 | — | $38,208 | — | -0.22% | +25.11% | — |
| 2026-05-01 | Q4 2025 | — | -2.20 | — | $36,251 | — | +1.98% | +35.71% | +169.84% |
Showing last 2 quarters.